Dyadic International (DYAI) Long-Term Deferred Tax (2020 - 2026)
Dyadic International (DYAI) posted Long-Term Deferred Tax of $19.3 million for Q1 2026, up 1.58% sequentially from $19.0 million in Q4 2025, and up 1.05% YoY from $19.1 million in Q1 2025.
Dyadic International (DYAI) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Dyadic International has reported Long-Term Deferred Tax for 7 years, with the latest figure at $19.3 million in Q1 2026.
- Quarterly Long-Term Deferred Tax rose 1.05% year-over-year to $19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (up 1.05% YoY) and the FY2025 annual result came in at $19.0 million, up 7.95% from the prior year.
- Long-Term Deferred Tax rose to $19.3 million in Q1 2026 per DYAI's latest filing, from $19.0 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $19.3 million in Q1 2026 and troughed at $15.2 million in Q1 2022.
- A 5-year average of $17.4 million and a median of $17.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax jumped 49.02% in 2022, then advanced 1.05% in 2026.
- Over 5 years, Long-Term Deferred Tax stood at $15.5 million in 2022, then climbed by 5.81% to $16.4 million in 2023, then grew by 7.32% to $17.6 million in 2024, then gained by 7.95% to $19.0 million in 2025, then increased by 1.58% to $19.3 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $19.3 million, $19.0 million, and $19.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.30 Mn |
| Dec 31, 2025 | 19.00 Mn |
| Sep 30, 2025 | 19.20 Mn |
| Jun 30, 2025 | 18.80 Mn |
| Mar 31, 2025 | 19.10 Mn |
| Dec 31, 2024 | 17.60 Mn |
| Sep 30, 2024 | 17.70 Mn |
| Jun 30, 2024 | 17.80 Mn |
| Mar 31, 2024 | 17.70 Mn |
| Dec 31, 2023 | 16.40 Mn |
| Sep 30, 2023 | 17.10 Mn |
| Jun 30, 2023 | 17.10 Mn |
| Mar 31, 2023 | 16.90 Mn |
| Dec 31, 2022 | 15.50 Mn |
| Sep 30, 2022 | 15.70 Mn |
| Jun 30, 2022 | 15.70 Mn |
| Mar 31, 2022 | 15.20 Mn |
| Dec 31, 2021 | 13.00 Mn |
| Sep 30, 2021 | 12.60 Mn |
| Jun 30, 2021 | 12.60 Mn |